Other
Intravitreal Injections
0
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Intravitreal Injections is an early-stage landscape with 0 programs across 3 companies. The most active players are AbbVie, Novartis, Unity Biotechnology, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
28
clinical trials
Completed20 · 71%
Unknown status5 · 18%
Not yet recruiting2 · 7%
Terminated1 · 4%
Clinical Trials
Trial Activity
28 trials
Ocular Discomfort Assessment After Intravitreal Injections
Completed·—·N/A·NCT02806830·45 enrolled
Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
Completed·—·Phase 4·NCT03246152·31 enrolled
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
Completed·AAssociation for Innovation and Biomedical Research on Light and Image·Phase 2·NCT01281098·22 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)